Weight Loss Diets

The next issue (June 22, 2015) of The Medical Letter will include an article on Saxenda, a new formulation of the GLP-1 receptor agonist liraglutide that has been approved by the FDA for chronic weight management. Liraglutide was already available as Victoza for treatment of type 2 diabetes, and the observation that diabetes patients treated with liraglutide lost weight led to the development of the new formulation. The FDA approval of Saxenda specifies that it should be used as an adjunct to diet and exercise. Information on diets, other drugs, and bariatric surgery is available in issue 1462 of The Medical Letter (February 15, 2015) on Diet, Drugs, and Surgery for Weight Loss.

Enter your email address to follow this blog and receive notifications of new posts by email.

Leave a Reply:

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s